Category Archives: News

Hurricane Lala Devastates Hawaii Island, Recovery Efforts Expected to Take Weeks

Honolulu, August 20: Hawaii Island has entered a long recovery phase after Hurricane Lala battered the region with torrential rain, powerful winds and severe flooding, leaving thousands of residents without electricity and causing extensive damage to critical infrastructure.

The Kaʻū district on the southern part of the island suffered some of the heaviest destruction, with washed-out roads, collapsed bridges, landslides and fallen trees isolating several communities. Emergency crews continue to clear debris and restore access to affected areas.

Power restoration remains a major challenge, with thousands of households still experiencing outages as utility teams work to repair damaged transmission lines and electrical infrastructure. Authorities have also reported damage to homes, public facilities and transportation networks across the island.

Beyond Hawaii Island, Hurricane Lala disrupted daily life on Maui and Oahu, where strong winds and heavy rainfall triggered localized flooding and damaged residential and commercial properties.

State and local agencies are coordinating relief operations while assessing the full extent of losses. Officials have warned that rebuilding roads, bridges and essential services in the worst-hit communities could take several weeks, urging residents to avoid damaged infrastructure and follow emergency safety advisories.

Hurricane Lala is among the most destructive storms to impact Hawaii in recent years, highlighting the growing challenges posed by extreme weather events across the Pacific.

PM Modi Likely to Address UN General Assembly High-Level Session in New York

New Delhi, August 20: Prime Minister Narendra Modi is expected to address the high-level segment of the 81st United Nations General Assembly (UNGA) in New York next month, as world leaders gather to deliberate on pressing global challenges and the future of multilateral cooperation.

According to the preliminary programme, Modi is scheduled to speak during the afternoon session on September 25. The session is currently slated to continue from 3 p.m. to 9 p.m. local time, although the final speaking schedule could undergo changes.

The high-level segment of the UNGA is scheduled to commence on September 22, bringing together heads of state and government from across the world. The 81st session will be chaired by Bangladesh Foreign Minister Khalilur Rahman, who was elected President of the UN General Assembly in June.

This year’s UNGA theme is “Restoring trust, managing transformation: A United Nations that delivers for all.” Discussions are expected to focus on strengthening international cooperation and addressing geopolitical, economic and development challenges facing the global community.

Modi has participated in several high-level UNGA sessions since assuming office in 2014. His upcoming address is expected to provide an opportunity for India to highlight its priorities on global development, multilateral cooperation and emerging international challenges.

The UNGA week is also likely to see a series of bilateral and informal engagements among world leaders on the sidelines of the main sessions.

More than a Tire Store: Goodyear Opens First Farm Experience Center in India

PUNE, India, Aug. 20, 2026 /PRNewswire/ — Buying farm tires has traditionally been a transaction. With the opening of India’s first Farm Experience Center in Pune, Goodyear is turning it into an experience.

Transforming a traditional dealership into an experience-led destination, the center enables farmers, dealers, and OEM partners to explore products, experience Goodyear’s technology and receive expert consultation in one place. It also showcases Goodyear’s latest farm tire portfolio, including the recently launched Ultra Grip tractor tire, designed specifically for Indian farming conditions.

“The Goodyear Farm Experience Center represents a new way for customers to engage with our brand,” said Arvind Bhandari, Chairman & Managing Director, Goodyear India Ltd., “It reflects our commitment to creating deeper, more meaningful connections by combining trusted expertise, greater accessibility and a more customer-focused approach.”

“Farm tire requirements vary significantly across crops, terrains and operating conditions,” said Ganga Nandan Mishra, Vice President, Goodyear India Farm & Commercial PBU. “By bringing our portfolio and technical expertise together in one place, the center helps customers and partners better understand their options and identify solutions suited to their specific needs.”

The initiative supports Goodyear India’s transformation toward experience-led retail, strengthening customer engagement, brand perception, and premium growth. Building on the Goodyear Consumer Experience Center approach, it also shows how the model can be adapted to different markets and business needs.

About The Goodyear Tire & Rubber Company

Goodyear is one of the world’s largest tire companies. It employs about 63,000 people and manufactures its products in 48 facilities in 19 countries around the world. Its two Innovation Centers in Akron, Ohio, and Colmar-Berg, Luxembourg, strive to develop state-of-the-art products and services that set the technology and performance standard for the industry. For more information about Goodyear and its products, go to www.goodyear.com/corporate.

About Goodyear India Limited

Goodyear India Limited has had a presence in India for over 104 years. Its manufacturing facility, located in Ballabgarh, Faridabad, produces automotive tires, including farm tires and commercial truck tires. In the farm segment, the Company supplies tires to all major tractor OEMs in India. Additionally, Goodyear India trades in passenger car tires and offers technologically advanced products designed to enhance the driving experience. For more information about Goodyear India and its products, go to www.goodyear.co.in.

Goodyear in India also operates a manufacturing plant in Aurangabad, Maharashtra, where it manufactures consumer tires. Furthermore, Goodyear has established a Technology Centre in Hyderabad to support innovation and development.

CONTACT: 

HELEN PEI 

+86-18149784088

HELEN_PEI@GOODYEAR.COM 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/more-than-a-tire-store-goodyear-opens-first-farm-experience-center-in-india-302854385.html

Defense Tech Company Lyntris Raises $297.5 Million in IPO: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, Aug. 19, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on August 19th

• Defense tech firm Lyntris (NYSE: LYNX) will make its trading debut on the NYSE.
  • The firm sold 17 million shares at $17.50 apiece in its IPO.
  • Lyntris will begin trading under the ticker symbol LYNX.
• INDYCAR driver Marcus Ericsson to discuss the Freedom 250 Grand Prix.
  • Ericsson is coming off a victory at Markham last week.
  • The Freedom 250 Grand Prix takes place August 22-23.
• LATAM Airlines (NYSE: LTM) CFO Ricardo Bottas to join NYSE Live.
  • Bottas will join to discuss the firm’s Q2 earnings earlier this month.
  • The airline reported a year-over-year revenue increase of 28%.
• Investors await today’s Fed Minutes and react to the latest corporate earnings.
  • Approximately two-thirds of traders expect interest rates to hold steady.
  • Target (NYSE: TGT), TJX (NYSE: TJX) and Lowe’s (NYSE: LOW) reported earnings this morning.

Opening Bell

Russell Investments celebrates the launch of two new ETFs, CRIB and BD

Closing Bell

Citrotech (NYSE American: CITR) celebrates its uplisting to NYSE American

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/defense-tech-company-lyntris-raises-297-5-million-in-ipo-nyse-content-update-302855265.html

DrFirst Receives Frost & Sullivan’s 2026 North America Enabling Technology Leadership Recognition for Advancing AI-Enhanced Medication Orchestration

DrFirst is honored for redefining medication management with its scalable platform that embeds intelligence directly in prescribing, making it more efficient for providers, pharmacies, and patients.

SAN ANTONIO, Aug. 19, 2026 /PRNewswire/ — As healthcare organizations continue to navigate fragmented medication workflows, rising administrative complexity, and growing demands for faster patient access, DrFirst is transforming how prescriptions move from creation to fulfillment. The company is honored for its AI-enhanced medication orchestration platform with Frost & Sullivan’s 2026 North America Enabling Technology Leadership Recognition in Intelligent Medication Management, citing a new model of prescribing architecture that unites clinical insight, operational efficiency, and patient-centered care.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. DrFirst excelled in both, demonstrating its ability to align strategic initiatives with evolving healthcare demands while executing innovations that deliver measurable improvements across clinical workflows. “DrFirst has advanced beyond its traditional role as a workflow enabler to emerge as a leader in AI-enhanced medication orchestration, fundamentally redefining how prescription orders are created and executed across the care continuum,” said Sagar Mukhekar, Industry Analyst, Frost & Sullivan.

Guided by a long-term growth strategy focused on digital innovation, clinical intelligence, and stakeholder collaboration, DrFirst has evolved from a prescription workflow enabler into a comprehensive medication orchestration platform. By bringing real-time clinical, operational, and business context directly within prescribing workflows, the company helps providers make better-informed decisions while reducing administrative burden, speeding therapy initiation, and improving patient access to medications. A defining example is the concept of the “fully optimized prescription,” which arrives at the pharmacy ready to fill, with potential roadblocks resolved.

Innovation remains central to DrFirst’s approach. The company’s platform delivers actionable decision support throughout the prescribing process, helping providers resolve barriers before a prescription reaches the pharmacy. By addressing challenges such as prior authorization, coverage requirements, and pharmacy-specific considerations, fewer surprises happen downstream and patients start therapy sooner.

“Our investment in AI and agentic automation means we can surface the options available for each specific patient, resolve coverage and pharmacy roadblocks before the prescription is sent, and give the care team a path forward rather than another alert,” said Laizer Kornwasser, CEO of DrFirst. “This recognition from Frost & Sullivan affirms that intelligence belongs in the workflow, not alongside it.”

DrFirst’s commitment to customer experience further positions it as a leader in medication management. By connecting providers, pharmacies, pharmacy benefit managers (PBMs), and patients through a unified platform, the company simplifies complex workflows and improves coordination across the healthcare continuum. Its prescription engagement solution also helps strengthen provider-patient relationships, delivering personalized medication information that improves adherence and health outcomes.

Frost & Sullivan commends DrFirst for setting a high standard in competitive strategy, execution, and market responsiveness. Its sustained investment in AI, extensive industry experience, and deep stakeholder relationships are shaping the future of medication management. Through its scalable platform, DrFirst is helping healthcare organizations reduce friction, improve provider productivity, and deliver more effective patient care.

Each year, Frost & Sullivan presents the Enabling Technology Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition highlights forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.

Contact us: Start the discussion.

About DrFirst

For 25 years, healthcare IT pioneer DrFirst has empowered providers and patients to achieve better health through intelligent medication management. The company has won over 25 awards for excellence and innovation, including TIME’s list of the World’s Top HealthTech Companies of 2025, recognizing the company’s medication management solutions and integrated workflows that make every step of the patient journey easier, from first prescription to ongoing adherence. DrFirst solutions help over 100 million patients a year and are used by more than 670,000 providers, 71,000 pharmacies, 270 EHRs, and over 2,000 hospitals in the U.S. To learn more, visit DrFirst.com.

Contact:

Ashley Shreve

E: ashley.weinkauf@frost.com 

View original content:https://www.prnewswire.co.uk/news-releases/drfirst-receives-frost–sullivans-2026-north-america-enabling-technology-leadership-recognition-for-advancing-ai-enhanced-medication-orchestration-302852292.html

ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights

The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care.

JENA, Germany, Aug. 19, 2026 /PRNewswire/ — ZEISS Medical Technology, one of the world’s leading medical technology companies, today announced the 510k clearance from the U.S. Food and Drug Administration (FDA) for ZEISS CLINIC 360¹. An all-in-one cloud and browser-based software solution, ZEISS CLINIC 360 combines diagnostic and medical data into a comprehensive patient view. By making relevant information easy to access and review, the solution helps clinicians evaluate disease progression, support treatment decisions, and improve workflow efficiency. ZEISS CLINIC 360 is part of the ZEISS ophthalmic workflow portfolio and will be available in the U.S. in early Fall 2026.

“Our strategic focus on digitally connected workflows, combined with the increasing adoption of digital ophthalmic tools in the U.S., has firmly positioned ZEISS at the forefront of empowering ophthalmologists. As ophthalmology continues to adopt connected technologies, clinicians need solutions that fit seamlessly into how their practice operates,” says Federico Villegas, Head of ZEISS Medical Technology U.S. and President of Carl Zeiss Meditec USA, Inc. “ZEISS CLINIC 360 reflects our commitment to reducing complexity across the care journey and helping practitioners work more efficiently while maintaining focus on their patients, marking a significant advancement toward the delivery of more personalized patient care.”

“Practices are dealing with increasing volumes of information from imaging devices, medical records, and diagnostic testing. With ZEISS CLINIC 360, our game-changing, cloud-based solution presents a truly comprehensive view of a patient, supporting a wide range of practices with actionable clinical insights and flexible configurations,” says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. “ZEISS CLINIC 360 represents a new standard in patient care support, helping clinicians identify meaningful change more quickly and spend less time searching for what they need.”

With the introduction of ZEISS CLINIC 360, ZEISS now offers eye care providers the flexibility to choose the data management approach that best fits their needs. While ZEISS FORUM continues to provide robust on-premise data management for practices that prefer local infrastructure, ZEISS CLINIC 360 delivers a cloud-based alternative that provides flexibility and scalability in a subscription-based model with low upfront costs and predictable monthly or annual payments.

Create a comprehensive patient overview

Combining information from diagnostic devices, electronic medical records, and practice systems, ZEISS CLINIC 360 creates a comprehensive patient record that allows clinicians to view their DICOM-enabled diagnostic device data – including CIRRUS^®, CLARUS^® and HFA^® from ZEISS, as well as third-party devices – to gain a unified, multi-modality view, enabling faster, more informed decisions to deliver high-quality, personalized care. ZEISS CLINIC 360 includes EMR integration² that seamlessly consolidates critical patient data – including risk factors, family history, allergies, and more – into the clinical workflow, organizing medical and diagnostic data together to present a comprehensive view of the patient’s condition.

Gain actionable clinical insights 

Leveraging disease-based summaries, interactive analysis, and collaboration tools, ZEISS CLINIC 360 transforms data into actionable clinical insights to enhance patient care. Clinicians can quickly monitor glaucoma progression, for example, with intuitive color-coded alerts and trend analysis of OCT, IOP and Visual Field data. ZEISS CLINIC 360 streamlines the clinical workflow with automated, interactive tools and analyses, providing greater efficiency across the workflow. When consultation is needed, clinicians can securely share cases and reports and request input from colleagues through integrated access to the ZEISS Collaborative Care feature, helping to facilitate improved patient care and referrals.

Designed for different clinical practice models

Built on the ZEISS Health Data Platform, ZEISS CLINIC 360 is accessed through the cloud or a web-based browser, enabling clinicians to review information across locations without requiring local software installation. Subscription options allow practices to select the configuration that best aligns with their operational and clinical requirements.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Contact for investors:

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220 116

Mail: investors.med@zeiss.com

Contact for the press:

Frank Smith

Head of Global Communications

Ophthalmology, Carl Zeiss Meditec Inc.

Phone: +49 3641 220 331

Mail: press.med@zeiss.com

Company Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/zeiss-clinic-360-receives-fda-510k-clearance-amplifying-patient-care-through-simplified-clinical-insights-302854994.html

Next Level Aviation® Appoints Mike Fleener as Senior Vice President of Global Sales

DANIA BEACH, Fla., Aug. 19, 2026 /PRNewswire/ — Next Level Aviation^® (NLA), a leader in the global distribution of used serviceable materials (USM) for all Boeing and Airbus commercial aircraft and associated jet engine platforms, has appointed Michael Fleener as Senior Vice President – Global Sales.

As a United States Military Academy graduate, former Army officer and Apache attack helicopter pilot who also has 20+ years in the commercial aviation aftermarket, Mr. Fleener brings significant leadership, sales, operations and supply chain experience to Next Level Aviation^®. Throughout his career, Mr. Fleener has worked in various roles for many of the largest companies in the commercial aviation aftermarket, including an OEM.

In his new role, Mike will leverage his leadership experience to lead, manage, develop and expand Next Level Aviation’s global sales team to grow its USM business in the coming years. He will also work closely SVP-Global Business Development Clive Rankin to expand Next Level Aviation’s global customer base.

Next Level Aviation^® CEO Jack Gordon commented, “We are pleased to add Mike Fleener as SVP-Global Sales at Next Level Aviation^®.” Gordon continued, “After 20 years in the commercial aviation aftermarket, Mike understands the USM needs of, and how to frame NLA’s value proposition to, our target end-user customers of airlines, leasing companies, MROs and OEMs. His analytical approach, willingness to mentor our existing sales team, and experience delivering results in fast-paced operating environments is exactly what Next Level Aviation^® needs to help drive this next stage of company growth.”

Senior Vice President – Global Sales Mike Fleener stated, “I am excited to join Next Level Aviation^® at such an important stage in the company’s growth. NLA has built an outstanding reputation for customer service, industry expertise, and delivering high-quality USM solutions to its global customer base. I look forward to working with the entire NLA team to expand our global customer relationships, develop our talented sales organization, and create long-term value for our customers and business partners.”

About Next Level Aviation^®

Next Level Aviation^® is an ASA-100 accredited, and FAA Advisory Circular 00-56B compliant supplier stocking commercial aircraft/jet engine used serviceable material (USM) for all Boeing and Airbus aircraft platforms and associated jet engines. Next Level Aviation^® specifically focuses on stocking USM for the Boeing 737 and Airbus A320 families of aircraft and their associated jet engines, which currently make up about 65% of the global commercial fleet. Founded in March 2013 by Jack Gordon, Next Level Aviation^® has grown into a top global supplier of commercial aircraft/jet engine used serviceable material. www.nextlevelaviation.net

To find out more information or to request additional images, please contact morgane@aerospacemarketing.com.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/next-level-aviation-appoints-mike-fleener-as-senior-vice-president-of-global-sales-302854422.html

Dubai Police Initiatives Drive $176.4 Million in Social Value and Gains in Safety, Wellbeing and the Economy, Study Reveals

DUBAI, UAE, Aug. 19, 2026 /PRNewswire/ — A study has estimated the Social Return on Investment (SROI) of 80 Dubai Police community initiatives at AED 647.9 million ($176.4 million), reflecting the wider social, economic and security value created for 3.8 million beneficiaries between 2017 and 2026.

Conducted by the Future Foresight Centre, the study examined initiatives across education, health, awareness and sport and measured their contribution to security, economic and social outcomes, including public safety, crime prevention, trust in police and quality of life.

The study found that economic and community contributions accounted for AED 542.7 million ($147.8 million) of the total SROI. Initiatives supporting quality of life generated AED 31.7 million ($8.6 million), while AED 62.8 million ($17.1 million) was attributed to initiatives contributing to public trust. A further AED 5 million ($1.36 million) was linked to community wellbeing, while AED 5.7 million ($1.55 million) came from initiatives promoting accessibility and opportunities for participation across society.

The research also examined statistical relationships between community initiatives and key security and social indicators. It found positive correlations of 0.44 with the Happiness Index, 0.45 with the Happiness, Security and Awareness Index, and 0.44 with enhanced perceptions of safety.

The analysis also identified inverse relationships with crime related indicators. Increased implementation of community initiatives coincided with lower levels of concerning crimes, recording a negative correlation of 0.41. The study also found a negative 0.796 correlation between customer happiness and crime rates.

Lieutenant General Abdulla Khalifa Al Marri, Commander-in-Chief of Dubai Police, said the results reflect the effectiveness of developing sustainable community initiatives around society’s needs, while strengthening community partnerships and supporting quality of life. He described community initiatives as an important pillar of sustainable security, contributing to trust in police, perceptions of safety and crime prevention.

Among the initiatives assessed, ‘Positive Spirit’ initiative reached two million people, while Esaad benefited more than 1.15 million. Ride with Dubai Police reached 40,000 people, while activities associated with the UAE SWAT Challenge benefited 51,000.

The study also found that 7,189 volunteers contributed 249,916 hours between 2017 and 2026, generating estimated financial savings of AED 21.7 million ($5.9 million).

The findings show how sustained community engagement can translate into measurable social and economic value while supporting preventive security, stronger public trust, improved quality of life and greater social stability.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/dubai-police-initiatives-drive-176-4-million-in-social-value-and-gains-in-safety-wellbeing-and-the-economy-study-reveals-302855312.html

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

HONG KONG, Aug. 19, 2026 /PRNewswire/ — Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs are what it pursues; patients are why it does what it does. This philosophy aligns with the Company’s mission, “Science for a Healthier World.”

The unified identity reflects the Company’s strategic evolution from a leading domestic biopharmaceutical company into a global innovator. This transformation is advancing on two fronts: product globalization, by building a global pipeline of innovative assets through in-house R&D and acquisition; and business globalization, through global partnerships and direct commercial expansion in key international markets. Supported by continued investment in global talent, organizational capabilities and infrastructure, the Company aims to bring innovative medicines to more patients worldwide.  

“2026 marks the first year of executing our globalization strategy, and we have made strong progress,” said Ms. Theresa Tse, Chairwoman of the Board. “SBP Group is committed to working with global partners to accelerate the global development and availability of innovative medicines from China and bring cutting-edge therapies from around the world to China. Leveraging our AI-driven, fully integrated R&D platform, we aim to advance breakthroughs at the frontiers of science, with the ultimate goal of benefiting more patients and improving human health.”

To date, the Company has completed four out-licensing transactions with MNCs, with aggregate upfront payments exceeding US$1 billion and a total potential deal value of more than US$7 billion, alongside over 30 M&A, licensing and strategic partnership transaction. 2026 key transactions include (i) the exclusive licensing to Sanofi of rovadicitinib, a first-in-class dual JAK/ROCK inhibitor, in a transaction valued at up to US$1.53 billion; and (ii) the exclusive licensing to AstraZeneca of TQC3721, an inhaled PDE3/4 inhibitor for COPD, in a transaction valued at up to US$1.9 billion.

About SBP Group

Sino Biopharmaceutical Limited (HKEX: 01177), referred to herein as “SBP Group”, is a leading innovation-driven pharmaceutical company in China. The Company has end-to-end capabilities across full value chain, including R&D, manufacturing and commercialization. Its product portfolio covers a wide range of biologics and small molecule drugs, with a strong leadership position across four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sino-biopharmaceutical-limited-unveils-new-global-brand-sbp-group-to-accelerate-international-expansion-302855206.html

Bybit’s RLUSD Hold & Earn Surpasses $50M AUC, Launches Phase 2 with Boosted XRP-RLUSD Rewards in Partnership with Ripple

DUBAI, UAE, Aug. 19, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to announce its exclusive RLUSD Hold & Earn program is entering Phase 2, extending its partnership with Ripple. Starting now, the upgraded Bybit Earn campaign introduces dual daily rewards in both XRP and RLUSD, with total annualized returns scaling based on holding duration.

Bybit’s RLUSD Hold & Earn program, initially launched in July this year, accumulated over $50 million in Assets Under Custody (AUC) within 11 days, attracting yield-seekers with its simple structure, flexibility, and minimum hassle. Eligible Bybit users may simply hold RLUSD with no staking or lock-up required, drawing popular demand from holders seeking stable, low-friction yield opportunities.

Highlights – Phase 2

The second phase of the program retains the same user experience with added benefits, introducing APR multipliers for holders both by volume and by length of time:

• Dual-Token Rewards: Participants can now earn both RLUSD at a competitive base APR and XRP with bonus APR daily
• XRP Base APR Multiplier: Users who maintain their holdings for 30 days or more receive up to 2x bonus on the XRP portion, more than doubling the potential total APR
• Smooth User Journey: No subscription, no lock-up. Holding RLUSD is all it takes to earn APR automatically

XRP rewards are brought to the Bybit community by Ripple’s milestone-based incentive program, enabling holders to get the most of the Ripple ecosystem assets with confidence.

RLUSD is a USD-backed stablecoin issued by Ripple. Natively issued on XRP Ledger, Ethereum, and other blockchains. RLUSD is fully backed by a segregated reserve of cash and cash equivalents and redeemable 1:1 for US dollars. As a regulated, reserve-backed digital asset, RLUSD offers the price stability of traditional cash in onchain form.

Terms and conditions apply. For more details on the APR multiplier, eligibility, and potential restrictions, users may visit: RLUSD Hold & Earn Phase 2: Earn Up to 21.5% APR in XRP + RLUSD

#Bybit  / #NewFinancialPlatform

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That’s why we’re building the first intelligent platform that connects anyone, anywhere to the world’s finance.

Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/bybits-rlusd-hold–earn-surpasses-50m-auc-launches-phase-2-with-boosted-xrp-rlusd-rewards-in-partnership-with-ripple-302855213.html